Prostate-Specific Antigen (PSA) screening for Prostate Cancer (PCa): Main recommendations
Abstract Prostate cancer is the most frequent type of cancer diagnosed in men and is the second cause of cancer death in the United States. The widespread use of Prostate-Specific Antigen since the early 1990s has significantly increased its incidence. However, screening for prostate cancer remains one of the most controversial topics in the urologic literature. The latest clinical evidence suggests that screening does not affect all-cause mortality and has only a small effect on prostate-specific mortality. At the same time, there are risks associated with biopsy and prostate cancer treatment, such as urinary incontinence, infection, and erectile dysfunction. Current recommendations propose shared decision-making with the patient but differ, with respect to the appropriate ages for screening, as well as follow-up screening intervals.
| Main Authors: | , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Sociedad Mexicana de Urología
2021
|
| Online Access: | http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2007-40852021000200010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|